Tridge Life Sciences Fund, LP
Raised
Pre-open
Investors
—
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
Tridge Life Sciences Fund, LP is a Delaware limited partnership filing under Rule 506(b) and Section 3(c)(1), managed by Tridge Capital Management, LLC and Tridge Capital GP, LLC. This is a pre-open filing with no disclosed capital raised, investor count, or minimum investment at the time of submission. The fund invests in longevity biotech assets through a pooled investment vehicle structure.
This longevity biotech fund follows the standard 506(b)/3(c)(1) exemption pattern typical of private biotech investment vehicles targeting accredited investors. The pre-open filing with undisclosed terms is common for institutional life sciences funds establishing regulatory compliance prior to initial close.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
- Tridge Capital Management, LLC
Executive Officer, Promoter · NEW YORK, NY
- Tridge Capital GP, LLC
Executive Officer, Promoter · NEW YORK, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.